The Molecular Biology of Paroxysmal Nocturnal Hemoglobinuria (PNH)
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||The Molecular Biology of Paroxysmal Nocturnal Hemoglobinuria (PNH)|
- Identify the mutation causing the predominant clones through analysis of extracted DNA/RNA from erythroid colonies [ Time Frame: After sample is obtained ] [ Designated as safety issue: No ]
- Reconfirmation of PrP expression in human granulocytes, hematopoietic progenitors and stem cells [ Time Frame: After sample is obtained ] [ Designated as safety issue: No ]
- Analysis of PrP function in human long term hematopoietic stem cells [ Time Frame: After sample is obtained ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
|Study Start Date:||May 2006|
|Study Completion Date:||December 2010|
|Primary Completion Date:||December 2010 (Final data collection date for primary outcome measure)|
Subjects suspected of having Paroxysmal Nocturnal Hemoglobinuria (PNH)
Paroxysmal nocturnal hemoglobinuria (PNH) is characterized by hemolytic anemia, thrombosis, and variable cytopenia. It can be associated with significant morbidity including acute kidney failure, cerebral infarction, mesenteric infarction, Budd-Chiari syndrome, aplastic anemia, and leukemic transformation. The average survival time from diagnosis is 15 years.
PNH is an acquired clonal disorder of the hematopoietic stem cell. Two distinct populations of hematopoietic cells exist in each PNH patient: one non-clonal population of normal cells, and one clonal population of PNH cells. The clonal population of PNH cells is identified by a mutation in the PIG-A gene that results in absence of the glycophosphatidylinositol (GPI) anchor of several surface proteins. Consequently, these surface proteins are unable to perform their functions on the cell surface. Deficiency of two of these surface proteins, CD55 (decay accelerating factor) and CD59 (membrane inhibitor of reactive lysis) that prevent complement mediated destruction, have been shown to underlie the clinical presentation of PNH. Identifying the mutation causing the predominant clones may help us better understand the molecular biology of PNH. When this is accomplished, new therapies to control and eventually cure the disease can be designed.
In addition, we propose to determine the function of PrP in human hematopoietic stem cells. PrP is a glycoprotein attached to the cell membrane by a glycosylphosphatidylinositol (GPI) anchor. In PNH, a disorder whose pathogenesis lies in the absence of GPI anchors, PrP expression is reduced in monocytes and granulocytes from the PNH clone.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00721864
|United States, Utah|
|University of Utah|
|Salt Lake City, Utah, United States, 84132|
|Principal Investigator:||Josef T Prchal, MD||University of Utah|